"While weight loss is crucial for metabolic health, this study reveals that diet composition, specifically a ketogenic approach, can offer significant additional benefits for liver fat reduction and blood sugar control, even when weight loss is matched across different dietary patterns."
A groundbreaking controlled feeding trial has illuminated a critical distinction in the impact of various diets on liver health, even when the amount of weight lost is identical. The research, conducted by Washington University School of Medicine in St. Louis, indicates that a ketogenic diet may provide a more potent therapeutic effect on reducing liver fat and improving glycemic control compared to Mediterranean and low-fat plant-forward diets, irrespective of equivalent weight loss. This finding challenges the prevailing notion that weight loss is the sole driver of metabolic improvements, suggesting that the specific macronutrient composition of a diet plays a significant, independent role in combating conditions like non-alcoholic fatty liver disease (NAFLD) and prediabetes in individuals with obesity.
The controlled feeding trial enrolled 55 adults grappling with metabolically unhealthy obesity, prediabetes, and diagnosed fatty liver disease. Participants were meticulously assigned to one of three distinct dietary regimens: a ketogenic diet, a Mediterranean diet, or a low-fat plant-forward diet. The core of the study’s innovative design lay in its rigorous control over calorie intake, ensuring that every participant achieved approximately a 10 percent reduction in their starting body weight over a period of roughly five months. This meticulous approach, where researchers supplied 100 percent of participants’ food and provided weekly consultations with a study dietitian, was instrumental in isolating the effects of diet composition from the confounding variable of differing weight loss amounts.
The results, which analyzed data from 42 participants, revealed a striking divergence in liver fat reduction. While all three dietary groups experienced significant improvements in muscle insulin sensitivity, with an average increase of about 50 percent, the impact on liver fat was markedly different. The ketogenic group achieved an impressive average reduction of 67 percent in liver fat. In contrast, both the Mediterranean and low-fat plant-forward groups saw an average decrease of 45 percent in liver fat. This disparity, observed despite similar overall weight loss, underscores the unique metabolic advantages potentially conferred by a very low-carbohydrate, high-fat ketogenic diet in the context of fatty liver disease.
Beyond liver fat, the ketogenic diet also demonstrated a more pronounced impact on glycemic control. By the conclusion of the trial, approximately half of the participants in the ketogenic group no longer met the diagnostic criteria for prediabetes. This contrasts with 29 percent in the Mediterranean group and a mere 7 percent in the plant-forward group. Furthermore, the study observed a more substantial improvement in insulin sensitivity within liver cells for those on the ketogenic diet, with improvements two to three times greater than the other groups. This enhanced liver insulin sensitivity is crucial, as it governs the liver’s ability to suppress glucose production, thereby contributing to better blood sugar regulation.
The hormonal mechanisms behind these observed benefits are also illuminating. Participants adhering to the ketogenic diet exhibited a significant drop in 24-hour blood glucose levels, decreasing by 20 percent from their baseline, compared to an 8 percent reduction in the other groups. Concurrently, circulating insulin levels across the day saw a dramatic fall of 74 percent in the ketogenic group, versus 44 percent and 27 percent in the Mediterranean and high-carbohydrate groups, respectively. The study also noted a notable increase in glucagon, a hormone that plays a role in mobilizing stored fat from the liver, among those on the ketogenic diet. These hormonal shifts align with the observed reductions in liver fat and improved glycemic control.
Samuel Klein, the senior author of the study and a professor at Washington University School of Medicine, emphasized the implications of these findings: "We know weight loss can improve metabolic health in people who are obese," he stated. "Our data suggest that if you have high liver fat content and prediabetes, reducing carbohydrate intake can have important therapeutic effects on metabolism beyond just weight loss alone." This sentiment highlights a paradigm shift in understanding metabolic disease management, moving beyond a singular focus on the number on the scale.
One of the most surprising findings for the investigators was the absence of an average increase in blood fat or cholesterol levels among participants on the high-fat ketogenic diet. Max Petersen, the first author of the study, commented on this unexpected outcome: "The most surprising finding was that participants in the ketogenic diet group didn’t experience an increase in blood fat or cholesterol levels despite consuming the most fat." However, it is crucial to add a significant caveat to this observation. Individual responses to very low-carbohydrate diets can vary considerably, and some individuals may indeed experience substantial increases in LDL cholesterol. Therefore, the group average should not be interpreted as a universal prediction for every individual.
The researchers were also transparent about potential conflicts of interest. The study received funding from the National Institutes of Health and the Foundation for Barnes-Jewish Hospital. Samuel Klein reported advisory board fees from AbbVie, 89bio, and Boehringer Ingelheim, a grant from Merck, and support for an industry-initiated trial from Viking Therapeutics. This disclosure is essential for a complete understanding of the research landscape.
The practical implications of this trial are significant, particularly given the prevalence of fatty liver disease. Petersen noted that fatty liver disease affects roughly 75 percent of adults with obesity worldwide and is the fastest-growing cause of chronic liver disease and cirrhosis, often progressing silently until advanced stages. Obesity itself is a widespread condition, affecting about four in ten American adults. Clinicians commonly recommend various dietary patterns, including low-fat, low-carbohydrate, or Mediterranean approaches, often without robust evidence differentiating their metabolic advantages beyond weight loss. This trial aimed to fill that evidentiary gap.
However, the researchers and the scientific community strongly caution against extrapolating these findings directly to everyday dietary choices without careful consideration. The trial’s small sample size of 42 analyzed participants means it is insufficient to detect rare adverse effects or to generalize findings across diverse populations in terms of age, sex, ethnicity, and baseline health status. Furthermore, the five-month duration does not provide insight into the long-term sustainability of these dietary patterns, whether liver fat remains reduced over extended periods, or if the observed metabolic advantages persist after weight stabilization. The controlled environment, including free food and weekly professional support, is a significant departure from real-world conditions.
Certain individuals should exercise particular caution and consult with a healthcare professional before embarking on a ketogenic diet. This includes people with specific kidney conditions, pregnant individuals, those with a history of disordered eating, and individuals managing diabetes with medication. Carbohydrate restriction, especially without proper medical guidance and potential medication adjustments, can lead to dangerously low blood sugar levels (hypoglycemia).
Petersen also contextualized these findings within the broader landscape of obesity treatment, acknowledging the growing role of medications like GLP-1 agonists, which have proven effective for weight loss. "Many metabolically unhealthy patients also are candidates for GLP-1 medicines, which have been very useful tools for helping people lose weight," he said. "But our results show that choice of diet remains important because it has an impact on specific health outcomes that go beyond weight loss alone." This suggests that a comprehensive approach, potentially integrating dietary strategies with pharmacological interventions, may be the most effective path forward.
Currently, no professional medical body has altered its dietary recommendations based solely on this trial, and such a move would be premature given the study’s limitations. Existing guidance for fatty liver disease continues to emphasize a weight loss of approximately 7 to 10 percent, coupled with regular physical activity, alcohol reduction, and effective management of diabetes and lipid profiles.
Future research is crucial to solidify these findings. A larger, longer-term trial is needed to ascertain whether the reduction in liver fat translates into tangible clinical outcomes, such as a decreased incidence of cirrhosis, liver cancer, and cardiovascular events. Imaging-based assessment of liver fat is considered a surrogate marker, and its long-term clinical significance requires further validation.
For individuals currently managing fatty liver disease, the immediate takeaway from this research is nuanced yet significant: the method by which weight is lost may be as important as the amount. This is a critical point to discuss with healthcare providers during appointments, alongside requests for imaging or fibrosis assessments that can objectively track improvements in liver health. The journey toward better metabolic health is multifaceted, and understanding the specific impacts of dietary choices is an increasingly vital component of effective management.
